Symptoms and General Pathology

All Conditions

Heart and Blood Diseases

Neoplasms

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Gland and Hormone Related Diseases

Nutritional and Metabolic Diseases

Syndrome

Hypertension

Polycystic Ovary Syndrome

Metabolic Syndrome

Insulin Resistance

Hyperinsulinism

Metabolic Diseases

Glucose Metabolism Disorders

Cysts

Ovarian Cysts

Ovarian Diseases

Adnexal Diseases

Genital Diseases, Female

Genital Diseases

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Gonadal Disorders

Endocrine System Diseases

All Drugs and Chemicals

Vasoconstrictor Agents

Respiratory System Agents

Androgens

Epinephrine

Racepinephrine

Epinephryl borate

Women who met the 2003 Rotterdam criteria, which require a minimum of two of the following three criteria:

1. Oligo- or anovulation
2. Clinical and/or biochemical signs of hyperandrogenism
3. Polycystic ovaries and exclusion of other etiologies (congenital adrenal hyperplasia, androgen-secreting tumors, Cushing's syndrome)

Ming-I Hsu, MD

Polycystic ovary syndrome (PCOS) is an extremely common disorder in women of reproductive age. Diagnosis of PCOS is principally based on clinical and physical findings. Diagnostic criteria and PCOS definitions used by clinicians and researchers are almost as heterogeneous as the syndrome. Of those diagnosed with PCOS using the 2003 Rotterdam criteria, 61% fulfilled 1990 NIH criteria for unexplained hyperandrogenic chronic anovulation. The patient populations with the new phenotypes had less severe ovulatory dysfunction and less androgen excess than patients diagnosed using the 1990 NIH criteria. These findings might be common across all female populations with PCOS, whether in Oriental or Occidental countries. Data for clinical hyperandrogenism indicated that the prevalence of hirsutism in Taiwanese PCOS women is lower than that for Caucasians/Western women.

The extent of metabolic abnormalities in women with PCOS may vary with phenotype, age and ethnicity. Obesity represents a major risk factor for metabolic syndrome and insulin resistance. Approximately 40-50% of all women with PCOS are overweight or obese. Obese subjects with PCOS had a higher risk of developing oligomenorrhea, amenorrhea and biochemical hyperandrogenemia than non-obese women with PCOS. Moreover, obese women with PCOS had significantly more severe insulin resistance, lower serum LH levels, and lower LH-to-FSH ratios than non-obese women with PCOS. PCOS women in Taiwan presented with higher LH-to-FSH ratio and lower insulin resistance than PCOS women in Western Countries. However, the average body mass index (BMI) was significantly lower in Taiwanese PCOS women than Western women, which might partially explain the difference between these two populations in terms of clinical and biochemical presentations.

To further document the ethnic variation between women with PCOS in Taiwan and Western, the effect of obesity on the diagnosis and clinical presentations of PCOS-related syndromes should not be neglected in future studies. Therefore, the investigators plan to do this prospective study for evaluation the clinical and biochemical presentation of Taiwanese women with PCOS.

1. Method

1. This study was approved by the Institutional Review Board of the Wan Fang Medical Center at Taipei Medical University (WF99041, approved August 2010) and performed at the Reproductive Endocrinology Clinic at the Wan Fang Medical Center from 31 August 2010 to 31 August 2011. The following women were excluded: (i) women who had been diagnosed with hyperprolactinemia, hypogonadotropic hypogonadism, premature ovarian failure, congenital adrenal hyperplasia, androgen-secreting tumor,Cushing's syndrome, disorders of the uterus and chromosomal anomalies; (ii) women who were less than three years past menarche or who were older than 45 years; (iii) women who received hormones or medication for major medical diseases (diabetes or cardiovascular disease); and (iv) women who had had ovarian cysts or ovarian tumors identified by ultrasonographic examination.
2. Statistical analysis: We used chi-squared and Fisher's exact tests to perform categorical comparisons and ANOVA to compare the continuous variables. The means of more than two groups were compared using one-way ANOVA and post hoc Dunnett's t-test with equal variances not assumed.

To Study Polycystic Ovary Syndrome in Taiwanese Women

Using serum total testosterone to represent the severity of hyperandrogenism.

BMI categorization was based on the WHO Asia-Pacific classification for obesity, which was defined as BMI ≧ 25 kg/m2(WHO: Obesity: preventing and managing the global epidemic. Geneva: WHO; 2000).

A fasting serum insulin level of greater than the upper limit of normal for the assay used (approximately 60 pmol/L) is considered evidence of insulin resistance.

Fasting blood sugar (FBS) measures blood glucose after you have not eaten for at least 8 hours. It is often the first test done to check for prediabetes and diabetes.

World Health Organization 2006 diagnostic criteria for diabetes were employed (fasting plasma glucose ≥7.0 mmol/L or two hour plasma glucose ≥11.1 mmol/L).

2-hour postprandial blood sugar measures blood glucose exactly 2 hours after you start eating a meal. This is not a test used to diagnose diabetes.

World Health Organization 2006 diagnostic criteria for diabetes were employed (fasting plasma glucose ≥7.0 mmol/L or two hour plasma glucose ≥11.1 mmol/L).

HOMA-IR = \[fasting insulin (in μIU/mL) × fasting glucose (in mg/dL)\]/405.

Hypercholesterolemia was defined as \>6 mmol / L.

Abnormal serum triglycerides defined as ≥ 1.7 mmol/L

Metabolic syndrome was defined (2005 National Cholesterol Education Program, Adult Treatment Panel III) as the presence of at least three of the following criteria:

abdominal obesity (waist circumference \>80 cm in women); serumtriglycerides≥1.7 mmol/L; serumHDL\<1.3 mmol/L; systolic blood pressure ≥130 mmHg and/or diastolic blood pressure ≥85 mmHg; and fasting plasma glucose ≥7.0 mmol/L.

Lipid profiles, including total cholesterol, triglycerides, high-density lipoprotein (HDL), low-density lipoprotein (LDL) and sex hormone binding globulin (SHBG).

Abnormal LDL was ≧4.14mmol/L.

Impaired glucose tolerance was defined as two hour glucose levels of 7.8-11.1 mmol/L in the 75 g oral glucose tolerance test. In women with impaired glucose tolerance, the fasting plasma glucose level should be \<7 mmol/L.

Taipei Medical University WanFang Hospital

Attending Doctor

Control

PCOS

Total

Age, Continuous

Sex: Female, Male

Taiwan

Region of Enrollment

Dr. Ming-I Hsu

Total Testosterone

Fasting Insulin

Fasting Glucose

Two Hour Glucose

Homeostasis Model Assessment Insulin Resistance Index (HOMA-IR)

Cholesterol

Triglycerides

BMI categorization was based on the WHO Asia-Pacific classification for obesity, which was defined as BMI ≧ 25 kg/m2(WHO: Obesity: preventing and managing the global epidemic. Geneva: WHO; 2000).

Women who met the 2003 Rotterdam criteria, which require a minimum of two of the following three criteria:

1. Oligo- or anovulation
2. Clinical and/or biochemical signs of hyperandrogenism
3. Polycystic ovaries and exclusion of other etiologies (congenital adrenal hyperplasia, androgen-secreting tumors, Cushing's syndrome)

Obese With PCOS

Obese With Control

BMI categorization was based on the WHO Asia-Pacific classification for obesity, which was defined as BMI \< 25 kg/m2(WHO: Obesity: preventing and managing the global epidemic. Geneva: WHO; 2000).

Women who met the 2003 Rotterdam criteria, which require a minimum of two of the following three criteria:

1. Oligo- or anovulation
2. Clinical and/or biochemical signs of hyperandrogenism
3. Polycystic ovaries and exclusion of other etiologies (congenital adrenal hyperplasia, androgen-secreting tumors, Cushing's syndrome)

Non-obese With PCOS

BMI categorization was based on the WHO Asia-Pacific classification for obesity, which was defined as BMI \< 25 kg/m2(WHO: Obesity: preventing and managing the global epidemic. Geneva: WHO; 2000).

Nonb-obese With Control

Impaired Glucose Tolerance

Overall Study

Skin and Connective Tissue Diseases

Breast Neoplasms

Breast Diseases

Skin Diseases

Women received clinical breast examination

Chen-Pin Chou, MD

To investigate whether digital breast tomosynthesis (DBT) benefits survival improvement.

To suggest DBT for specific populations, compare the overall survival rate of women with digital mammography (DM) to the DBT screening for women with particular characteristics.

The Effect of Digital Breast Tomosynthesis in Breast Cancer Long-term Survival: a Single Institution Study

The data that support the findings of this study are available on reasonable request from the corresponding author. Some data are not publicly available due to their containing information that could compromise the privacy of research participants.

Compare the overall survival rate according to breast density type, cancer stage, mammography test type, and imaging modality.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
To Study Polycystic Ovary Syndrome in Taiwanese Women	NCT01256944	Polycystic Ovar... Metabolic Syndr... Cardiovascular ...		15 Years - 45 Years	Taipei Medical University WanFang Hospital
To Study Polycystic Ovary Syndrome in Taiwanese Women	NCT01256944	Polycystic Ovar... Metabolic Syndr... Cardiovascular ...		15 Years - 45 Years	Taipei Medical University WanFang Hospital
The Effect of Digital Breast Tomosynthesis in Breast Cancer Long-term Survival: a Single Institution Study	NCT05600257	Breast Cancer	DBT DM	23 Years - 89 Years	Kaohsiung Veterans General Hospital.
The Effect of Digital Breast Tomosynthesis in Breast Cancer Long-term Survival: a Single Institution Study	NCT05600257	Breast Cancer	DBT DM	23 Years - 89 Years	Kaohsiung Veterans General Hospital.

Spots Global Cancer Trial Database for dm

Every month we try and update this database with for dm cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for dm

Every month we try and update this database with for dm cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for dm cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.